The effect of anxiety and personality on the pharmacokinetics of oral midazolam.
We investigated the relationship between the pharmacokinetic variables of oral midazolam and patients' state/trait anxiety and personality. Twenty-six patients received the standard 15-mg oral dose for anxiolysis on the evening before otorhinolaryngological surgery. Blood samples were taken over a 9-h period after the administration, and the samples were analyzed for concentrations of midazolam and its two main metabolites by using a gas chromatography-mass spectrometry procedure. The pharmacokinetic variables maximum concentration, time to reach the maximum concentration, the elimination half-life, and the area under the curve were calculated from these data. When the patients were divided into groups with respect to their anxiety and personality scores, no significant differences in the pharmacokinetic variables of midazolam could be found. Only small, insignificant changes in the maximum concentrations were found with respect to nervousness and emotionality. We conclude that personality traits and anxiety levels had no effect on the pharmacokinetic variables of midazolam.


CONCLUSIONS
We conclude that personality traits and anxiety levels had no effect on the pharmacokinetic variables of midazolam. Therefore, it is not necessary to obtain anxiety or personality scores to find the proper midazolam dose for the individual patient.
Martens-Lobenhoffer
J
J
Institute of Clinical Pharmacology, University Hospital, Magdeburg, Germany.
Eisenhardt
S
S
Tröger
U
U
Röse
W
W
Meyer
F P
FP
D000284:Administration, Oral; D000328:Adult; D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics*; D001007:Anxiety / Q000378:metabolism*; D019540:Area Under Curve; D005260:Female; D006801:Humans; D008297:Male; D008874:Midazolam / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D010551:Personality
D014151:Anti-Anxiety Agents; D008874:Midazolam